Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET Cohort.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
09 Apr 2024
Historique:
accepted: 28 03 2024
received: 07 08 2023
revised: 28 03 2024
medline: 9 4 2024
pubmed: 9 4 2024
entrez: 9 4 2024
Statut: aheadofprint

Résumé

Inhibitor development is the most severe complication of hemophilia A care, and is associated with increased morbidity and mortality. The aim of this study was to use a novel IgG epitope mapping method to explore the factor VIII (FVIII)-specific epitope profile in the SIPPET cohort population and to develop an epitope-mapping based inhibitor prediction model. The population consisted of 122 previously untreated patients with severe hemophilia A that were followed-up for 50 days of exposure to FVIII or 3 years, whichever occurred first. Sampling was performed before FVIII treatment and at the end of the follow-up. The outcome was inhibitor development. The FVIII epitope repertoire was assessed by means of a novel random peptide phage-display assay. A LASSO regression model and a random forest model were fitted on post-treatment sample data and validated in pre-treatment sample data. The predictive performance of these models was assessed by the C-statistic and a calibration plot. We identified 27,775 peptides putatively directed against FVIII, which were used as input for the statistical models. The C-statistic of the LASSO and random forest models were good at 0.78 (95%CI: 0.69-0.86) and 0.80 (95%CI: 0.72-0.89). Model calibration of both models was moderately good. Two statistical models, developed on data from a novel random peptide phage display assay, were used to predict inhibitor development before exposure to exogenous FVIII. These models can be used to set up diagnostic tests that predict the risk of inhibitor development before starting treatment with FVIII.

Identifiants

pubmed: 38593222
pii: 515674
doi: 10.1182/bloodadvances.2023011388
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Shermarke Hassan (S)

Leiden University Medical Center, Netherlands.

Guido Baselli (G)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Luca Mollica (L)

L.I.T.A/University of Milan, Milan, Italy.

Riccardo L Rossi (RL)

Bioinformatics, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Italy.

Himani Chand (H)

University of Milan, Milan, Italy.

Amal Mohamed El-Beshlawy (AM)

Cairo University, Giza, Egypt.

Mohsen Saleh Elalfy (MS)

Ain Shams University, Cairo, Egypt.

Vijay Ramanan (V)

Jehangir Hospital Premises, Pune, India, Pune, India.

Peyman Eshghi (P)

Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Childern's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of.

Mehran Karimi (M)

American Hospital Dubai, United Arab Emirates.

Roberta Palla (R)

Università degli Studi di Milano, Milan, Italy.

Frits R Rosendaal (FR)

Leiden University Medical Center, Leiden, Netherlands.

Flora Peyvandi (F)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,, Italy.

Classifications MeSH